Clinical Trials Browser

Phase 1/2 × INDUSTRY × Bevacizumab × Clear all

NCT05101070 2026-03-18

aCCeleR8-001

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors

NCT07479485 2026-03-18

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

Phase 1/2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT03786081 2026-03-13

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Phase 1/2 Active not recruiting

Uterine Cervical Neoplasms

NCT06445062 2026-03-13

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 1/2 Recruiting

Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT07079631 2026-03-06

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05579366 2026-03-03

RAINFOL-01

Phase 1/2 Recruiting

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04068610 2026-03-02

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Phase 1/2 Active not recruiting

61 enrolled 35 charts

Gastrointestinal

Colonic Neoplasms

NCT05797168 2026-03-02

FONTANA

Phase 1/2 Recruiting

GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04524871 2026-02-27

MORPHEUS-LIVER

Phase 1/2 Recruiting

Advanced Liver Cancers

NCT05083481 2026-02-27

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT05739981 2026-02-27

MRD

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07391566 2026-02-06

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Solid Cancer

NCT06697197 2026-02-03

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT04626635 2026-02-02

COMBINE-EGFR-1

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT05867420 2026-01-27

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT05584670 2026-01-20

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07080216 2026-01-05

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

Phase 1/2 Recruiting

Uterine Cervical Neoplasms

NCT06512051 2025-12-23

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07298772 2025-12-23

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT06730750 2025-12-15

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT03337698 2025-12-12

Morpheus Lung

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT05908786 2025-12-11

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT06703177 2025-12-03

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07244705 2025-11-24

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Phase 1/2 Recruiting

Gastrointestinal

Disease, Colorectal Neoplasms

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Phase 1/2 Completed

341 enrolled 28 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT04660812 2025-10-20

ARC-9

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT06796907 2025-10-14

BEHOLD-2

Phase 1/2 Recruiting

Neoplasms

NCT05609370 2025-10-02

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06840002 2025-09-30

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

Phase 1/2 Recruiting

Ovarian Neoplasms

NCT05589597 2025-08-22

AUDREY

Phase 1/2 Terminated

Gastrointestinal

Colorectal Cancer Metastatic

NCT06953323 2025-08-13

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT07044908 2025-08-12

TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

RAS/BRAF Wild Type Colorectal Cancer

NCT06859775 2025-06-06

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Phase 1/2 Recruiting

Uterine Cervical Neoplasms, Recurrence

NCT06922383 2025-04-15

A Clinical Study of Arfolitixorin in Patients With mCRC

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03829410 2025-03-04

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

Phase 1/2 Completed

68 enrolled 21 charts

Gastrointestinal

Colorectal Neoplasms

NCT03169790 2025-02-24

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Phase 1/2 Withdrawn

Lymphoma, Non-Hodgkin

NCT03167164 2025-02-21

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Phase 1/2 Withdrawn

Carcinoma, Merkel Cell

NCT03167177 2025-02-21

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Melanoma

NCT03169738 2025-02-21

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03169777 2025-02-21

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Phase 1/2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Carcinoma, Transitional Cell

NCT02078648 2025-02-03

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Phase 1/2 Completed

74 enrolled 19 charts

Glioblastoma